National Health (Originator Brand) Amendment Determination 2020 (No. 5) (PB 85 of 2020) (Cth)

PB 85 of 2020

National Health (Originator Brand) Amendment Determination 2020 (No. 5)

I, Thea Daniel, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination.

Dated   26        August 2020               

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)    2

1  Name

This instrument is the National Health (Originator Brand) Amendment Determination 2020 (No. 5).

This instrument may also be cited as PB 85 of 2020.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 September 2020

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 99ADB(6B) of the National Health Act 1953

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1  Schedule 1, (table item 143)

Repeal the items:

143 Metformin Diabex Diabex 850 Diabex 1000 Diabex XR Diabex XR 1000

Substitute:

143 Metformin Diabex Diabex 850 Diabex 1000 Diabex XR 500 Diabex XR 1000

2  Schedule 1, (table item 156)

Repeal the items:

156	Morphine	Hospira Pty Limited	Injection
MS Contin MS Contin Suspension 100 mg MS Contin Suspension 20 mg MS Contin Suspension 200 mg MS Contin Suspension 30 mg MS Contin Suspension 60 mg

Substitute:

156	Morphine	DBL Morphine Pentahydrate	Injection
MS Contin MS Contin Suspension 100 mg MS Contin Suspension 20 mg MS Contin Suspension 200 mg MS Contin Suspension 30 mg MS Contin Suspension 60 mg

3  Schedule 1, (table item 207)

Repeal the items:

207 Salbutamol Ventolin Rotacaps Ventolin CFC‑free Ventolin Ventolin Nebules

Substitute:

207 Salbutamol Ventolin Rotacaps Ventolin CFC‑free Ventolin CFC-Free with dose counter Ventolin Nebules

4  Schedule 1, (table item 229A)

Repeal the items:

229A	Tobramycin	Hospira Pty Limited Pfizer Australia Pty Ltd	Injection
		Tobi	Inhalation
		TOBI podhaler	Inhalation by mouth
		Tobrex	Application to the eye

Substitute:

229A	Tobramycin	DBL Tobramycin Pfizer Australia Pty Ltd	Injection
		Tobi	Inhalation
		TOBI podhaler	Inhalation by mouth
		Tobrex	Application to the eye